Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201210-02 Development of a Candidate for Antidepression by Triple Reuptake Inhibition(CNS Diseases, Chemical) [01.18.2013]

PRINT

Development and Market Objectives

· Development of a candidate to major depressive disorder (MDD), which simultaneously inhibits reuptake of neurotransmitters including serotonin, norepinephrine and dopamine, while exhibiting low side-effects.

Unmet Medical Need & Target Patients

· Depression is one of the most common mental disorders frequently referred to as the “cold of the mind,” which affects approximately 17% of the world's population at least once in a lifetime.

· For the treatment of depression, drugs that inhibit reuptake of neurotransmitters serotonin, norepinephrine and dopamine have been used. However, several side effects persist (thirst, constipation, dysuria, visual disturbances, impotence, abnormal blood pressure caused by adverse effects on the cardiovascular system, abnormal pulse rate, cardiac conduction, orthostatic hypotension, and sedation).

· The medicinal effects of drug administration are also not immediate; a disadvantage is low remission rates and a time delay of several weeks or months. Thus, the development of drugs for the treatment of depression with less side-effects and high efficacy is urgently needed.

Status

· A new compound that inhibits reuptake of typical neurotransmitters including serotonin, norepinephrine and dopamine has been discovered.

· This compound exhibits biological activity in several hundred-fold compared to existing drugs in cell-line experiments, and it is stable in vivo. It also exhibits high permeability of the BBB, which is prerequisite in drug efficacy of the central nervous system.

· In addition, it exerts high efficacy in animal experiments using mouse models on depression.

Intellectual Property

· Korean patent application No. 10-2011-0089820 (2011, 09, 05)

· PCT application No. PCT/KR2012/007076 (2012, 09, 04)

· Scope of rights: Functions as an anti-depressant and inhibits reuptake of neurotransmitters such as serotonin, norepinephrine and dopamine as a cyclic compound that simultaneously contains new nitrogen.

Competitive Advantages

· The compound in this study differs from existing depression treatments as its structure is significantly different from the structure of existing drugs, which are currently on sale or under development.

· As existing drugs only inhibit reuptake of only one or two among the three major neurotransmitters serotonin, norepinephrine and dopamine, the effect of treatment is limited. However, the compound mentioned simultaneously inhibits reuptake of three neurotransmitters, and has a medicinal effect much higher than that of existing drugs.

· In addition, since this drug exhibits a high efficiency in delivery to the brain, it is expected to have a high efficacy at trace amounts and low side-effects.

Indication

Depression

Research Period

JAN.1,2013~JUN.30,2014

Company

Korea Institute of Science and Technology, Chemical Kinomics Research Center

Developmental Stage

Lead compound

Additional Information

Contact Information

Contact
Address Company Name: Korea Institute of Science and Technology, Chemical Kinomics Research Center
WebSite Homepage: http://www.kist.re.kr Contact Person: HohGyu, Hahn
E-mail: hghahn@kist.re.kr Contact: +82-2-958-5139

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code